Mary Jo Lamberti

New research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.

New research sheds fresh light on a trend with serious consequences for the public health-not only in the United States but for patients worldwide.